| ASPR | Office of the Assistant Secretary for Preparedness and Response |
| BARDA | Biomedical Advanced Research and Development Authority |
| BIO | Biotechnology Industry Organization |
| BLA | biologics license application |
| CBRN | chemical, biological, radiological, and nuclear |
| CDC | Centers for Disease Control and Prevention |
| CIDRAP | Center for Infectious Disease Research and Policy |
| CMC | chemistry, manufacturing, and controls |
| CPTR | Critical Path to TB Drug Regimens |
| DMID | Division of Microbiology and Infectious Diseases (NIAID) |
| DoD | Department of Defense |
| DST | drug susceptibility testing |
| EFPIA | European Federation of Pharmaceutical Industries and Associations |
| EMA | European Medicines Agency |
| EU | European Union |
| EUA | emergency use authorization (FDA) |
| EVD | Ebola virus disease |
| FDA | Food and Drug Administration |
| FRMM | Flu Risk Management Meeting |
| FSG | Foundation Strategy Group |
| GSK | GlaxoSmithKline |
| HHS | Department of Health and Human Services |
| IND | investigational new drug application |
| IOM | Institute of Medicine |
| IRAT | Influenza Risk Assessment Tool |
| MCM | medical countermeasure |
| MERS | Middle East respiratory syndrome |
| MERS-CoV | Middle East respiratory syndrome coronavirus |
| NGDS | Next Generation Diagnostics System |
| NIAID | National Institute of Allergy and Infectious Diseases |
| NIH | National Institutes of Health |
| NPV | net present value |
| OTA | Other Transactions Authority |
| PCAST | President’s Council of Advisors on Science and Technology |
| PHEMCE | Public Health Emergency Medical Countermeasures Enterprise |
| PMO | phosphorodiamidate morpholino oligomer (Sarepta Platform) |
| qPCR | quantitative reverse transcriptase polymerase chain reaction |
| rVSV-ZEBOV-GP | recombinant vesicular stomatitis virus-based vaccine for the Zaire ebolavirus expressing EBOV glycoprotein (Merck Ebola Vaccine candidate) |